AKI and CKD. Read the timeline, perfusion, and urine together
Distinguish acute injury from chronic kidney disease using baseline trends, urine findings, perfusion, obstruction, and the decisions that protect kidney function.
A creatinine of 3 mg/dL can represent a new injury, established chronic disease, or both. The useful question is what changed, over what interval, and what is still reversible. Small kidneys support chronic damage; they do not excuse a new rise above baseline.
Read the timeline before assigning the cause. Then assess perfusion, urine drainage, and the injured kidney compartment together.
Establish what changed
Creatinine is a filtration marker with a delay. Its concentration also depends on muscle production, tubular secretion, and distribution volume. A frail patient can lose substantial filtration while creatinine remains inside the laboratory reference interval. During a changing creatinine, the automatically reported eGFR is not a reliable steady-state estimate for CKD staging. Compare actual measurements and urine output. [1][2]
AKI is a change, with three routes to diagnosis
Serum creatinine increases by at least 0.3 mg/dL within 48 hours.
Creatinine reaches at least 1.5 times baseline within the preceding 7 days.
Urine output is below 0.5 mL/kg/hour for at least 6 hours.
Any one criterion suffices. For example, 0.6 to 0.9 mg/dL in 36 hours is AKI even though 0.9 may look reassuring. Stage by the most severe creatinine or urine-output criterion reached. [1]
AKI severity in adults
Stage 1
Creatinine 1.5-1.9 times baseline or the 0.3 mg/dL rise. Urine output below 0.5 mL/kg/hour for 6 to less than 12 hours.
Stage 2
Creatinine 2.0-2.9 times baseline, or urine output below 0.5 mL/kg/hour for at least 12 hours.
Stage 3
Creatinine at least 3 times baseline, an acute rise to at least 4 mg/dL, or initiation of kidney replacement therapy. Alternatively, output below 0.3 mL/kg/hour for at least 24 hours or anuria for at least 12 hours.
CKD requires evidence of duration
CKD means abnormalities of kidney structure or function present for at least 3 months with health implications. Persistent eGFR below 60 mL/min/1.73 m² qualifies. At higher eGFR, persistent albuminuria, abnormal sediment, pathology, or structural abnormalities can establish CKD. One low eGFR during an illness cannot. Disease lasting weeks after AKI deserves follow-up without prematurely calling it CKD. [2]
Small echogenic kidneys with thin cortices support chronic parenchymal loss. Normal or enlarged kidneys do not exclude CKD, including diabetic disease, amyloidosis, HIV-associated disease, and polycystic disease. Anemia, secondary hyperparathyroidism, and broad waxy casts add context but are not clocks. A prior creatinine trend is often more informative than kidney size. Acute injury can occur in already scarred kidneys.
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 3
Show answer and explanations for case 3
A. Stage 2 AKI superimposed on CKD (Best answer)
The creatinine has more than doubled over days on a documented chronic baseline. Small kidneys support CKD but do not explain away the acute deterioration.
B. CKD alone because the kidneys are small (Why this does not fit)
Imaging supports chronic damage, but the abrupt doubling still requires evaluation for a reversible acute cause.
C. AKI alone because the latest change is rapid (Why this does not fit)
The 18-month reduction in eGFR establishes preexisting CKD in addition to the new injury.
D. Permanent kidney failure requiring immediate maintenance dialysis (Why this does not fit)
Neither kidney size nor this creatinine alone establishes irreversibility or an immediate dialysis indication. Treat acute causes and assess complications.
Takeaway: Acute and chronic disease can be true at the same time.
Blood reaches the afferent arteriole and glomerular capillaries. Is effective perfusion reduced by blood loss, dehydration, impaired cardiac function, or altered vascular tone?
Inside kidney tissue
Glomeruli filter; tubules process the filtrate. Is there tubular injury, interstitial inflammation, glomerular inflammation, or vascular injury?
After filtration
Urine drains through collecting ducts, calyces, renal pelvis, ureters, bladder, and urethra. Is back pressure opposing filtration?
This is a functional map, not a scale anatomical drawing. More than one location can contribute to the same AKI.
Prerenal physiology does not always mean dehydration
With reduced effective perfusion, preserved tubular function increases sodium and water retention. Diarrhea and hemorrhage reduce circulating volume. Heart failure may instead produce both impaired forward flow and renal venous congestion. A patient with raised jugular venous pressure and pulmonary edema may need decongestion, not an automatic saline bolus. Sepsis can combine altered perfusion with inflammatory tubular injury. [1]
NSAIDs inhibit prostaglandin-dependent afferent vasodilation, particularly when perfusion is already threatened. ACE inhibitors and ARBs reduce angiotensin-mediated efferent resistance. These hemodynamic effects can reduce filtration during hypovolemia or severe renovascular disease even though RAS blockade protects many patients with stable albuminuric CKD. Review recent drugs and illness before deciding whether a creatinine change reflects toxicity. [2]
Obstruction is actionable, but ultrasound is not always the first intervention
Check bladder distension, catheter patency, retention symptoms, pelvic malignancy, stones, and whether there is a solitary functioning kidney. Bilateral obstruction or obstruction of the only functioning kidney can cause substantial AKI. A single ureteral obstruction with a healthy opposite kidney usually does not explain a major global filtration decline. [3]
Ultrasound is appropriate urgently when the cause is unclear or obstruction is plausible, immediately when an infected obstructed system is suspected. Treat shock and dangerous hyperkalemia while investigating. Early obstruction can lack conspicuous hydronephrosis, so strong clinical suspicion survives an initially negative scan. Catheter drainage treats bladder outlet obstruction; upper tract obstruction may require a ureteral stent or nephrostomy. After drainage, monitor for post-obstructive diuresis, volume depletion, and electrolyte loss.
Use urine findings as evidence, not verdicts
Obtain urinalysis, microscopy when available, urine output, electrolytes, and a medication and volume assessment early. Casts form within renal tubules in a protein matrix. Their contents help localize disease; the same patient can have more than one process. [3][13]
Bland sediment or hyaline casts
Compatible with prerenal physiology. Hyaline casts can also occur with concentrated urine in otherwise healthy people. Bland urine does not exclude important kidney disease.
Muddy brown granular casts
Strong evidence for acute tubular injury, often called ATN. Ischemia or toxins injure epithelium and release cellular debris. The label does not mean every tubule is necrotic or recovery is impossible.
White-cell casts
Consider interstitial inflammation, including AIN and pyelonephritis. A new medication with sterile pyuria differs from fever, flank tenderness, and a positive urine culture.
Red-cell casts and dysmorphic RBCs
Strongly suggest glomerular bleeding. Proteinuria, hypertension, complement levels, and relevant serology help select urgent nephrology assessment and biopsy.
Intrinsic AKI also includes vascular disease. Thrombotic microangiopathy, including TTP and HUS, calls for a blood count, blood film and hemolysis assessment alongside the kidney evaluation. Tubular toxins include aminoglycosides, so review antimicrobial exposure as well as perfusion. [1]
Tubular segments do not respond identically to oxygen stress. The proximal S3 segment and medullary thick ascending limb are important sites in experimental hypoxic injury, with different responses to transport demand and metabolic inhibition. This explains regional vulnerability without requiring one uniform lesion in every clinical AKI. [19]
What sodium handling can and cannot tell you
FENa is 100 × (urine sodium × plasma creatinine) / (plasma sodium × urine creatinine), using paired samples with consistent units. Values below 1% support sodium avidity; values above 2% can support tubular dysfunction. Traditional prerenal patterns include urine sodium below 20 mmol/L, osmolality above 500 mOsm/kg, and BUN/creatinine above 20 when both are measured in mg/dL. Tubular injury often produces less concentrated urine, higher urine sodium, and a lower ratio. These are tendencies, not required diagnostic criteria.
Diuretics and CKD can increase FENa despite reduced perfusion. Glomerulonephritis, pigment injury, early obstruction, and some septic AKI can produce a low FENa despite intrinsic or postrenal disease. GI bleeding, catabolism, steroids, and low creatinine production alter the BUN/creatinine ratio. No single number outranks the examination and sediment. FEUrea below 35% is sometimes supportive of reduced perfusion, but loop diuretics can alter FEUrea too. [1][4]
Drug-associated AIN may occur without fever, rash, or eosinophilia. Urine eosinophils are neither sensitive nor specific enough to confirm it. Stop the suspected drug and assess alternatives; biopsy and corticosteroids are individualized with nephrology when injury persists or the diagnosis matters for treatment. [5]
After a recent streptococcal infection, a delayed nephritic illness with low C3 suggests poststreptococcal GN. Treat edema and hypertension, assess acute complications, and eradicate residual streptococci; a sore throat alone does not identify the glomerular diagnosis. [17]
Recognize the situations that defeat shortcuts
Muscle injury
After a crush injury, seizure, or severe exertional muscle injury, markedly increased CK and heme-positive urine with few RBCs suggest myoglobin. Dipstick heme can also reflect free hemoglobin, so it is not a myoglobin-specific test. Pigment toxicity, tubular obstruction, and hypovolemia can coexist. Give goal-directed isotonic crystalloid when appropriate, monitor potassium, and avoid forcing fluid into an anuric or overloaded patient. Routine bicarbonate or mannitol to prevent AKI is not supported. [11]
Contrast exposure
AKI after contrast is contrast-associated; timing alone does not prove contrast caused it. For intravenous iodinated contrast, ACR-NKF guidance favors saline prophylaxis for AKI or eGFR below 30 when not on maintenance dialysis and when fluid is appropriate. Selected high-risk patients at eGFR 30-44 may merit prophylaxis. Stable eGFR 45 does not require it merely because diabetes is present. Necessary diagnostic imaging should be weighed against the harm of a missed diagnosis. [6]
Cirrhosis with ascites
HRS-AKI involves circulatory dysfunction and renal vasoconstriction, but cirrhosis also permits sepsis, tubular injury, drug injury, and obstruction. The diagnostic criteria require cirrhosis with ascites, AKI, no improvement in creatinine and/or urine output within 24 hours after adequate volume resuscitation when indicated, and no strong alternative primary explanation. It can coexist with CKD or structural injury.
Current ADQI-ICA criteria do not require a routine 48-hour albumin infusion in everyone. Specialist treatment uses terlipressin as the first-line vasoconstrictor with carefully adjusted albumin; norepinephrine is an ICU-based alternative when terlipressin is unavailable or contraindicated. Assess candidacy for liver transplantation. Monitor oxygenation and volume because treatment can cause harm in an overloaded patient. [7]
A creatinine rise without a matching filtration decline
Trimethoprim can inhibit tubular creatinine secretion. A modest increase with unchanged urine output and cystatin C supports that explanation, although the same medication can also cause genuine AKI and hyperkalemia. In sarcopenia, creatinine-based eGFR may overestimate filtration; combined creatinine-cystatin C estimation can improve assessment. Cystatin C also has non-GFR determinants, including steroid exposure and thyroid dysfunction. [12][2]
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 21
Show answer and explanations for case 21
A. HRS-AKI is a serious possibility requiring prompt specialist treatment assessment (Best answer)
The cirrhosis-ascites setting and lack of response after appropriate resuscitation support consideration of HRS-AKI after evaluating alternatives.
B. Diagnosis requires giving albumin for 48 hours to every patient regardless of volume status (Why this does not fit)
The 2024 consensus rejects a universal 48-hour albumin requirement; unnecessary loading can harm a congested patient and delay treatment.
C. Any preexisting CKD makes HRS-AKI impossible (Why this does not fit)
HRS-AKI can occur on CKD and can coexist with structural kidney injury.
D. Failure to respond to fluid proves anatomically normal kidneys (Why this does not fit)
A clinical response pattern cannot prove normal histology. Tubular injury and other causes must still be assessed.
Takeaway: HRS-AKI requires a contextual diagnosis, not a compulsory fluid ritual.
Describe CKD by cause, filtration, and albumin leak
Use CGA classification. C names the cause, G describes eGFR, and A describes urine albumin/creatinine ratio. An eGFR without albuminuria misses an important part of risk. [2]
G1 or G2 needs another marker of kidney damage to establish CKD. Persistent eGFR 38 with ACR 650 is G3b A3, not simply “stage 3.”
RAS blockade reduces albuminuria through lower intraglomerular pressure. Check blood pressure, potassium, and creatinine after initiation or dose increase. SGLT2 inhibitors protect eligible adults with CKD, including many without diabetes. Their proximal tubular action can modify tubuloglomerular feedback and reduce hyperfiltration. A mechanistic study demonstrated reduced measured hyperfiltration in selected people with type 1 diabetes; that experiment does not establish routine prescribing in that population or prove that feedback is the sole mechanism of kidney benefit. [20] An expected modest initial eGFR dip alone is generally not a reason to discontinue them; assess an excessive decline or accompanying hypovolemia.
For adults with high blood pressure and CKD, a systolic target below 120 mmHg is suggested when tolerated using standardized office measurement. Frailty, falls and symptomatic postural hypotension can justify less intensive treatment. For metabolically stable adults with G3-G5 CKD, approximately 0.8 g/kg/day protein is a usual target, rather than indiscriminate severe restriction. [2]
G4 is an opportunity for education and planning. It is not an automatic order for a fistula. KDIGO suggests considering dialysis access or preemptive transplantation planning at eGFR below 15-20 or predicted kidney replacement risk above 40% over 2 years. Choose timing and modality with the patient, expected trajectory, transplant options, and local access lead times. G5 alone does not mandate dialysis. [2]
Treat the complication that is present
Anemia
Reduced erythropoietin contributes to a hypoproliferative, often normocytic anemia. Check reticulocytes, ferritin, transferrin saturation, and other causes before attributing everything to CKD. Iron deficiency can be normocytic. Inflammation raises hepcidin, limiting iron delivery despite stored iron. A high ferritin alone does not prove usable iron, but ferritin 2500 ng/mL with TSAT 45% does not justify routine additional iron. ESA initiation is individualized, especially off dialysis; do not aim to normalize hemoglobin. For adults receiving an ESA, KDIGO recommends a maintenance hemoglobin target below 11.5 g/dL. [8]
Mineral, bone, acid, and skin findings
Phosphate retention, altered FGF23 signaling, reduced calcitriol, and calcium balance promote secondary hyperparathyroidism. Calcium and phosphate can remain normal earlier in CKD. High-turnover osteitis fibrosa and low-turnover adynamic bone disease are different forms of renal osteodystrophy. Treat trends and contributing factors. Sevelamer binds dietary phosphate in the gut; in adults with G3a-G5 CKD who are not receiving dialysis, calcitriol is not routinely suggested. Severe, progressive hyperparathyroidism in G4-G5 is a setting in which it may be considered. [9]
Reduced net acid excretion can cause hyperchloremic metabolic acidosis; retained unmeasured anions may add an anion gap as disease advances. There is no fixed eGFR at which the pattern switches. Consider dietary and/or pharmacologic treatment when acidosis has potential clinical consequences, for example bicarbonate below 18 mmol/L in adults; monitor blood pressure, potassium and fluid status and avoid raising bicarbonate above the normal range.
Persistent generalized itch in dialysis has multiple neural, immune, and skin-barrier contributors. It is not proof of calcium-phosphate crystals. Skin care, dialysis review, and selected antipruritic treatment, including peripheral kappa-opioid receptor targeting, address different mechanisms. [2][10]
Severe hyperkalemia with ECG toxicity requires immediate IV calcium for cardiac stabilization while potassium-shifting treatment and elimination are arranged. Calcium does not lower potassium. Insulin with glucose requires subsequent glucose monitoring; refractory hyperkalemia may require dialysis. [18]
A visible action sequence
Stabilize dangerous potassium, pulmonary edema, shock, or uremic neurologic or pericardial disease.
Establish baseline and output, assess perfusion and drainage, review medications, and examine urine.
Treat the identified cause and reassess. Fluids help true depletion; persistent congestion needs a different plan.
Escalate unexplained or severe AKI, suspected GN, obstruction, or complications. Refractory acidosis, hyperkalemia, fluid overload, selected dialyzable poisonings, or symptomatic uremia can require dialysis. Do not wait for a particular creatinine.
Continuous kidney replacement therapy permits gradual fluid and solute control when circulation is unstable. It does not itself reverse the cause of AKI.
Arrange recovery monitoring, medication review, and reassessment for CKD by 3 months, earlier when clinically indicated.
[1][3] The current AKI guideline update remains a draft; this lesson uses published recommendations and separately verified newer topic guidance. [14]
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 39
Show answer and explanations for case 39
A. Defer dialysis until potassium again exceeds 6.5 mmol/L (Why this does not fit)
Corrected potassium does not negate symptomatic uremia. Pericarditis and encephalopathy can independently justify urgent kidney replacement therapy.
B. Arrange urgent kidney replacement therapy with nephrology (Best answer)
The attributed pericardial and neurologic complications are clinical dialysis indications. The decision is not contingent on a particular creatinine or recurrent hyperkalemia.
C. Use an NSAID as the sole treatment for the presumed uremic pericarditis (Why this does not fit)
This would not address the uremic state or encephalopathy and introduces additional kidney risk. Dialysis assessment is central to the described cause.
D. Give fluid solely to lower the measured creatinine (Why this does not fit)
No depletion is described, and dilution of a laboratory value does not treat symptomatic uremia. Fluid decisions require an independent volume assessment.
Takeaway: Symptomatic uremia can require dialysis even after potassium has been corrected.
A. Stage 1 because creatinine rose by only 0.3 mg/dL (Why this does not fit)
Use the higher stage supported by creatinine or output. The output criterion already exceeds stage 1 duration.
B. Stage 3 because output is below 0.3 mL/kg/hour (Why this does not fit)
This rate is about 0.29, but stage 3 requires that rate for at least 24 hours, or anuria for at least 12 hours.
C. Stage 2 because output is below 0.5 mL/kg/hour for at least 12 hours (Best answer)
Twenty divided by 70 is about 0.29 mL/kg/hour. Fourteen hours meets the stage 2 output criterion.
D. Stage 1 because the cumulative urine volume exceeds 200 mL (Why this does not fit)
AKI staging uses weight-normalized output over a stated duration, not a fixed daily volume. Here 20/70 is about 0.29 mL/kg/hour for 14 hours, meeting stage 2 but not the 24-hour low-output requirement for stage 3.
Takeaway: Duration matters as much as the urine output rate.
Diabetic CKD can occur with preserved or increased kidney size. The serial eGFR values already establish chronicity.
B. It does not overturn the established CKD diagnosis (Best answer)
Kidney size is supporting evidence, not the definition of CKD. Chronic laboratory abnormalities remain decisive here.
C. It establishes that the present decline is entirely acute (Why this does not fit)
Kidney length cannot date a filtration abnormality. The repeated low eGFR values over a year establish chronic dysfunction despite preserved length.
D. It makes obstruction the leading explanation for the low eGFR (Why this does not fit)
Normal length is not evidence of impaired drainage. Obstruction requires its own clinical and collecting-system assessment; it cannot be inferred from kidney length.
Takeaway: Normal-sized kidneys do not exclude advanced chronic disease.
A. Sodium retention can accompany renal congestion and reduced effective perfusion (Best answer)
Heart failure can activate sodium retention despite total-body fluid excess. The congestion argues for supervised decongestion, not reflex saline loading.
B. Low urine sodium definitively proves whole-body volume depletion despite the patient's edema (Why this does not fit)
Low effective arterial filling and venous congestion can coexist with marked edema, so a low urine sodium does not prove whole-body volume depletion.
C. The edema establishes nephrotic syndrome (Why this does not fit)
No heavy proteinuria or hypoalbuminemia is supplied; the cardiopulmonary findings offer a direct alternative explanation.
D. The creatinine rise proves irreversible tubular necrosis (Why this does not fit)
Creatinine does not identify histology. Congestion and hemodynamic changes can reduce filtration without proving irreversible tissue loss.
Takeaway: Low urine sodium does not choose the fluid prescription.
A. Efferent arteriolar dilation caused by reduced angiotensin II signaling during the illness (Why this does not fit)
That mechanism describes ACE inhibitor or ARB physiology, not the principal hemodynamic effect of ibuprofen in this setting.
B. Direct toxic injury to tubular epithelium (Why this does not fit)
Tubular toxicity can cause AKI, but the depletion, NSAID exposure and bland sediment favor a hemodynamic explanation here. Inhibition of prostaglandin-mediated afferent dilation further reduces filtration during low perfusion.
C. Drug-triggered inflammation of the interstitium (Why this does not fit)
NSAIDs can cause AIN, so this is a real alternative. The question asks about the additional filtration loss during acute depletion; the stated context favors impaired afferent vasodilation over an inflammatory lesion.
D. Reduced prostaglandin-dependent afferent vasodilation during depletion (Best answer)
When perfusion is compromised, prostaglandins help maintain afferent blood flow. NSAID inhibition can reduce glomerular pressure and filtration.
Takeaway: An NSAID becomes more hazardous when kidney perfusion already depends on compensatory vasodilation.
A. FENa proves acute tubular injury (Why this does not fit)
Furosemide increases sodium excretion and can raise FENa even when reduced perfusion is central.
B. FENa excludes obstruction (Why this does not fit)
Urine sodium indices are not a reliable exclusion test for urinary obstruction.
C. The diuretic limits FENa interpretation; integrate volume findings and sediment (Best answer)
The timing makes the index less discriminating. Examination, trajectory, medication exposure, and drainage assessment remain necessary.
D. The elevated FENa identifies chronic nephron loss as the primary explanation for the current kidney findings (Why this does not fit)
CKD can impair sodium conservation, but this patient has acute diuretic exposure and clinical depletion. FENa cannot establish chronicity or make chronic nephron loss the primary explanation.
Takeaway: A sodium-handling drug changes the meaning of a sodium-handling test.
A. Loop diuresis can change FEUrea, so the threshold crossing alone does not diagnose ATI (Best answer)
Prospective heart failure data show FEUrea can cross 35% after loop treatment. The entire clinical course still determines the diagnosis.
B. FEUrea is completely unaffected by loop diuretics (Why this does not fit)
That common shortcut is contradicted by observed changes during decongestion.
C. The crossing establishes a new acute tubular injury (Why this does not fit)
The same patient can cross the conventional threshold during loop treatment without a new tubular insult. Interpret the timing, sediment, filtration trend and volume findings together.
D. The FEUrea result proves intravascular depletion is now present and therefore requires saline replacement (Why this does not fit)
FEUrea alone cannot prove intravascular depletion or determine that a congested patient needs saline. Reassess circulation and congestion before changing the decongestion plan.
Takeaway: FEUrea is contextual evidence, not a diuretic-proof verdict.
A. Poststreptococcal glomerulonephritis (Why this does not fit)
The medication timing, rash, and sterile white-cell sediment favor interstitial inflammation rather than a red-cell glomerular pattern.
B. Isolated prerenal azotemia (Why this does not fit)
An inflammatory urine sediment and systemic drug reaction are not explained by reduced perfusion alone.
C. Chronic diabetic glomerulosclerosis (Why this does not fit)
The abrupt course following a new drug does not fit a chronic diabetic lesion as the main cause.
D. Drug-associated acute interstitial nephritis (Best answer)
The temporal exposure and inflammatory findings strongly support AIN. Withdraw the suspected drug and assess severity; biopsy may be needed if uncertainty affects treatment.
Takeaway: Drug timing and the whole inflammatory pattern are more useful than one urine marker.
A. Negative urine eosinophils exclude AIN (Why this does not fit)
Biopsy-referenced evidence shows poor sensitivity. A negative result does not rule out interstitial nephritis.
B. AIN remains plausible despite absence of the classic triad (Best answer)
PPI-associated AIN may lack dramatic hypersensitivity findings. Review the drug and consider nephrology evaluation or biopsy if the diagnosis remains consequential and uncertain.
C. Sterile pyuria proves bacterial pyelonephritis (Why this does not fit)
The negative culture and absence of a typical infectious syndrome weaken that conclusion; pyuria has noninfectious causes.
D. The timeline establishes CKD without further evaluation (Why this does not fit)
Several weeks do not establish the required chronicity, and a potentially treatable medication-associated injury is present.
Takeaway: Neither an absent triad nor negative urine eosinophils clears a suspected drug.
Lower urinary symptoms, systemic fever, flank tenderness, and bacteriuria point to an upper urinary infection. WBC casts support kidney inflammation in this context.
B. Drug-associated AIN (Why this does not fit)
AIN can cause WBC casts, but this stem provides a coherent bacterial infection pattern without a new drug exposure.
C. Anti-GBM glomerulonephritis (Why this does not fit)
The sediment is white-cell predominant with bacteriuria, not a glomerular red-cell syndrome or pulmonary-renal pattern.
D. Nephrotic syndrome (Why this does not fit)
No heavy proteinuria or hypoalbuminemia is described, and nephrosis does not explain fever and nitrite-positive urine.
Takeaway: The same cast type can have different causes; read it with the infectious history.
A. Assume the AKI is acute interstitial nephritis from lupus medications without evaluating other kidney causes (Why this does not fit)
Medication injury is possible, but RBC casts and low complement strongly direct attention to active glomerular disease, so other kidney causes cannot be skipped.
B. Classify the urine as bland prerenal sediment (Why this does not fit)
Dysmorphic erythrocytes and RBC casts are active glomerular findings.
C. Urgent nephrology assessment for active lupus nephritis and kidney biopsy when appropriate (Best answer)
The combination suggests inflammatory glomerular injury. Histologic class and activity guide treatment beyond the clinical syndrome.
D. Treat isolated cystitis as the complete explanation (Why this does not fit)
Cystitis does not adequately explain RBC casts, significant filtration loss, and hypocomplementemia.
Takeaway: An active glomerular sediment changes the urgency and the diagnostic pathway.
A. Give a large fluid bolus before addressing drainage (Why this does not fit)
The clear evidence of retention identifies an outflow problem; more fluid alone does not relieve it.
B. Relieve bladder outlet obstruction and monitor the response (Best answer)
Lower tract decompression addresses the demonstrated blockage. Track output, electrolytes, and possible postobstructive diuresis afterward.
C. Start glucocorticoids for interstitial inflammation (Why this does not fit)
There is no inflammatory evidence to displace the direct findings of urinary retention and bilateral dilation.
D. Repeat creatinine tomorrow before addressing the retention (Why this does not fit)
A large residual with bilateral hydronephrosis already identifies a treatable mechanical cause. Waiting solely for another creatinine can prolong injury.
Takeaway: A palpable full bladder and large residual make drainage an immediate priority.
A. Monitor closely and replace fluid and electrolytes according to serial assessment (Best answer)
Postobstructive salt and water losses can cause depletion and electrolyte disturbance. Replacement should be individualized to output, circulation, and laboratory trends.
B. Declare complete kidney recovery and discharge the patient because the urine output is now very high (Why this does not fit)
High output can reflect impaired concentrating and tubular function. Dizziness and falling potassium show that high urine output does not establish complete recovery.
C. Give unlimited fluid without measuring intake or output (Why this does not fit)
Unmeasured replacement can create new volume problems and misses the need for targeted electrolyte correction.
D. Restrict all intake until the polyuria stops (Why this does not fit)
The patient already has dizziness and potassium loss. Restricting replacement indiscriminately can worsen depletion and electrolyte disturbance.
Takeaway: Urine returning after decompression can create a new monitoring problem.
A. Treat this as isolated microscopic glomerular bleeding (Why this does not fit)
The heme signal without erythrocytes plus marked CK supports myoglobin rather than an RBC-driven glomerular syndrome.
B. Give mannitol and bicarbonate routinely to every patient with rhabdomyolysis to prevent kidney injury (Why this does not fit)
Routine mannitol and bicarbonate are not recommended to prevent rhabdomyolysis-associated AKI because evidence does not show reliable benefit.
C. Give goal-directed isotonic fluid, monitor potassium and output, and reassess for overload (Best answer)
Muscle breakdown releases myoglobin and potassium. Early volume management is useful, but persistent anuria or congestion requires adjustment rather than endless fluid.
D. Delay electrolyte testing until the CK normalizes (Why this does not fit)
Hyperkalemia can become dangerous early, well before CK has returned to normal.
Takeaway: Heme-positive urine with few RBCs prompts a pigment question, then immediate attention to circulation and potassium.
A. Dialysis must begin today because eGFR is below 20 (Why this does not fit)
The values support preparation, but dialysis initiation depends on symptoms, complications, preferences, and the wider clinical picture.
B. No education is needed until an emergency occurs (Why this does not fit)
High predicted risk and low eGFR justify timely modality and transplant discussions and access planning.
C. Every patient should receive a fistula first regardless of which kidney replacement treatment is ultimately chosen (Why this does not fit)
Access should fit the selected modality, transplant possibilities, prognosis, and personal goals. A fistula is not required before every other kidney replacement plan.
D. Discuss kidney replacement options and individualized access or preemptive transplant planning now (Best answer)
KDIGO supports planning at eGFR below 15-20 or two-year risk above 40%. Planning is distinct from immediate dialysis initiation.
Takeaway: Use trajectory and risk to prepare before complications force a rushed choice.
A. Reduced kidney erythropoietin signaling to marrow (Best answer)
The hypoproliferative pattern after evaluation of other causes fits deficient erythropoietic stimulation in CKD. ESA decisions remain individualized.
B. Increased peripheral RBC destruction (Why this does not fit)
Shorter red-cell survival can contribute in CKD, but the low reticulocyte count and absence of hemolysis favor impaired production from reduced EPO signaling as the most direct mechanism.
C. Depletion of iron available for hemoglobin synthesis (Why this does not fit)
Iron deficiency can be normocytic, so MCV alone cannot exclude it. Here adequate iron indices and no bleeding make deficient EPO signaling the better supported contributor.
D. Impaired DNA synthesis from folate deficiency (Why this does not fit)
Folate deficiency can suppress effective erythropoiesis, but the supplied folate and B12 assessment is normal. The kidney history and low reticulocyte response support EPO deficiency.
Takeaway: CKD anemia is an underproduction pattern after other treatable causes are assessed.
A. Ferritin alone proves abundant immediately usable iron (Why this does not fit)
Ferritin reflects stores and inflammation; it does not guarantee iron delivery to marrow when TSAT is low.
B. Iron-restricted erythropoiesis is plausible despite stored iron (Best answer)
Low circulating iron availability with retained stores can reflect hepcidin-mediated restriction. Assess iron treatment and other causes of ESA hyporesponsiveness together.
C. The indices prove iron overload requiring phlebotomy (Why this does not fit)
A TSAT of 12% indicates limited circulating availability, not the high saturation expected to support this conclusion.
D. ESA should be increased until hemoglobin is 14 g/dL (Why this does not fit)
Normalizing hemoglobin with ESA is not the goal; high targets carry risk and do not address limited iron availability.
Takeaway: Ferritin and TSAT answer different questions and must be interpreted together.
A. Give more iron because every anemia on dialysis is iron deficient (Why this does not fit)
These indices do not support routine additional iron, and anemia has other causes.
B. Ignore TSAT because ferritin is always falsely high (Why this does not fit)
Inflammation can increase ferritin, but the high TSAT also argues against giving routine additional iron.
C. Withhold routine iron and investigate the anemia and high indices (Best answer)
KDIGO advises withholding routine iron at ferritin above 700 or TSAT at least 40%. Review exposure, inflammation, blood loss, dialysis, and marrow or ESA factors.
D. Attribute the anemia entirely to iron deficiency and increase ESA without further assessment (Why this does not fit)
The indices do not establish iron deficiency, and an inadequate ESA response needs evaluation for other causes before simply escalating treatment.
Takeaway: The original high-ferritin, high-TSAT pattern must not be mislabeled as a reason for more iron.
A. It binds dietary phosphate within the gastrointestinal tract (Best answer)
The noncalcium binder reduces phosphate absorption when taken with food. It does not directly replace calcitriol or kidney filtration.
B. It activates vitamin D receptors to reduce PTH transcription (Why this does not fit)
That describes an effect of active vitamin D therapy. Sevelamer acts in the intestinal lumen, reducing phosphate absorption from food; taking it with meals matches that action.
C. It activates the calcium-sensing receptor on parathyroid cells (Why this does not fit)
That is the target of calcimimetic therapy. Sevelamer lowers absorbed phosphate by binding it in the gut, rather than directly activating the parathyroid receptor.
D. It increases urinary phosphate excretion through proximal tubules (Why this does not fit)
A phosphaturic mechanism requires meaningful residual kidney clearance. Sevelamer's intended effect is reduced intestinal phosphate absorption, which remains useful in dialysis.
Takeaway: Link the phosphate binder to the meal and the intestinal compartment.
Adynamic bone disease has low turnover, unlike the increased remodeling described.
B. High-turnover osteitis fibrosa (Best answer)
Excess PTH can produce a high-turnover fibrotic bone lesion in renal osteodystrophy.
C. Osteoporosis without a defined turnover abnormality (Why this does not fit)
Osteoporosis describes low bone strength and does not by itself explain increased remodeling with marrow fibrosis. The biopsy and severe hyperparathyroidism support osteitis fibrosa.
D. Osteomalacia defined by a mineralization defect (Why this does not fit)
Osteomalacia is a mineralization disorder. The biopsy instead identifies increased remodeling with marrow fibrosis in a high-PTH context.
Takeaway: High-turnover and low-turnover renal bone lesions are different diagnoses.
A. Anion gap 28 with a high-gap metabolic acidosis (Why this does not fit)
The gap is 140 minus the sum of 112 and 16, or 12 mmol/L. A result of 28 omits bicarbonate from the subtraction and misclassifies this hyperchloremic pattern.
B. Anion gap 12 with isolated respiratory acidosis (Why this does not fit)
The acidemia accompanies a low bicarbonate. PaCO2 of 34 is within the expected metabolic-acidosis compensation range of 1.5 × 16 + 8 ± 2, or 30-34 mmHg, rather than a primary respiratory acid load.
C. Anion gap 12 with a hyperchloremic metabolic acidosis pattern (Best answer)
The arithmetic gives 12, within many conventional laboratory ranges. Reduced net acid excretion in CKD can cause this pattern; use the local range and clinical assessment.
D. Anion gap 12 with metabolic acidosis plus respiratory alkalosis (Why this does not fit)
The calculated gap is correct, but PaCO2 of 34 is within the expected 30-34 mmHg compensation range. These measurements do not establish a second respiratory alkalosis.
Takeaway: Calculate the gap from the actual numbers before naming the acidosis.
A. Use nebulized albuterol alone before cardiac stabilization (Why this does not fit)
A beta-2 agonist can help shift potassium but does not replace immediate membrane stabilization for the widening QRS. Multiple treatments are needed.
B. Use an oral potassium binder as the only immediate treatment (Why this does not fit)
A binder may help eliminate potassium, but it does not promptly stabilize the electrically unstable myocardium. It cannot be the sole response here.
C. Withhold all temporizing therapy while dialysis access is arranged (Why this does not fit)
Dialysis may be necessary, but cardiac toxicity is present now. Calcium and potassium-shifting treatment should not wait for access placement.
D. Give IV calcium for cardiac membrane stabilization (Best answer)
Calcium addresses immediate electrical toxicity but does not lower potassium. Prompt potassium shifting and elimination, including dialysis when needed, must follow in parallel.
Takeaway: Treat the dangerous physiology immediately; calcium protects the heart while other therapies lower potassium.
A. It permits slower fluid and solute shifts during circulatory instability (Best answer)
Continuous therapy spreads fluid and solute control over time and is generally preferred in hemodynamically unstable AKI when available. It requires ongoing circulatory support and does not promise universal survival superiority.
B. It delivers a larger hourly solute clearance to normalize pH faster (Why this does not fit)
Standard intermittent hemodialysis generally delivers faster hourly clearance. The reason for favoring continuous therapy here is tolerance of gradual changes, rather than maximal speed.
C. It clears inflammatory mediators sufficiently to replace infection treatment (Why this does not fit)
Kidney replacement therapy treats fluid and metabolic complications. It does not replace antibiotics, source control or circulatory treatment for sepsis.
D. It requires a smaller total daily fluid loss for the same fluid balance goal (Why this does not fit)
The desired net fluid balance determines the amount to remove. Continuous therapy mainly changes the rate and distribution over time; it does not eliminate the existing fluid burden.
Takeaway: Choose the modality for current physiology without inventing a survival guarantee.
A. Interference with the laboratory creatinine assay (Why this does not fit)
The classic trimethoprim effect is a reduction in tubular secretion, causing a real serum creatinine increase. The primary physiologic study found no chemical interference with the assay.
B. Inhibition of tubular creatinine secretion (Best answer)
Trimethoprim can increase serum creatinine without a true fall in GFR. The unchanged independent filtration estimate supports this explanation here.
C. Drug-associated acute interstitial nephritis (Why this does not fit)
True AIN can occur during drug treatment, but the isolated small creatinine change with stable cystatin C, urine output and sediment better supports inhibited secretion in this case.
D. Tubular obstruction from drug crystals (Why this does not fit)
Crystalline injury can occur with some drugs, including the sulfonamide component of combination therapy. A matching filtration decline or urine findings would increase concern; the supplied isolated creatinine pattern favors inhibited secretion.
Takeaway: A creatinine rise can reflect altered secretion, but the drug is not thereby harmless.
A. Declare progressive irreversible tubular destruction (Why this does not fit)
A small early decline can reflect the expected hemodynamic effect and does not establish structural damage.
B. Automatically stop the drug permanently for any eGFR decline (Why this does not fit)
KDIGO notes that the reversible initial dip is generally not an indication to discontinue therapy.
C. Recognize a possible expected initial dip and continue with appropriate clinical monitoring (Best answer)
The modest change without dehydration or other injury evidence fits the expected early hemodynamic response. Investigate a larger or symptomatic decline.
D. Diagnose AIN from the eGFR change without additional findings (Why this does not fit)
AIN requires a compatible clinical assessment; a modest isolated dip after SGLT2 initiation does not establish interstitial inflammation.
Takeaway: An early hemodynamic dip can coexist with long-term kidney protection.
A. Peripheral kappa-opioid receptor activation (Best answer)
Difelikefalin targets this pathway in CKD-associated pruritus. The mechanism illustrates why itch is not simply proof of phosphate crystals in skin.
B. Histamine H1 receptor antagonism (Why this does not fit)
H1 blockade is the action of antihistamines, not difelikefalin. The trial drug targets peripheral kappa-opioid receptors in hemodialysis-associated pruritus.
C. Binding the alpha-2-delta subunit of voltage-gated calcium channels (Why this does not fit)
Binding this calcium-channel subunit is not the receptor action of difelikefalin. The studied drug is a peripheral kappa-opioid receptor agonist.
D. Mu-opioid receptor antagonism (Why this does not fit)
Mu antagonism is a different opioid-pathway intervention. Difelikefalin is a selective peripheral kappa-opioid agonist; the two receptor actions should not be conflated.
Takeaway: CKD-associated itch has multiple mechanisms even when mineral values are controlled.
A. Assume normal filtration because creatinine is within range (Why this does not fit)
Low muscle mass reduces creatinine generation and can make creatinine-based eGFR overestimate filtration.
B. Rely on BUN alone for a quantitative GFR estimate (Why this does not fit)
BUN varies with protein intake, catabolism, GI bleeding, and volume status. It cannot replace a more appropriate filtration assessment for medication decisions.
C. Average the historical and current creatinine values without adjusting for the patient's severe loss of muscle mass (Why this does not fit)
A numerical average does not correct the current low creatinine production from severe muscle loss and can obscure rather than resolve the uncertainty.
D. Consider cystatin C and a combined estimate, with measured GFR if uncertainty remains consequential (Best answer)
An additional filtration marker helps when creatinine generation is abnormal. Cystatin C also has non-GFR determinants, so interpret the combined evidence.
Takeaway: A reassuring creatinine can be misleading when little muscle is producing it.
A. The rise proves ACE inhibitor nephrotoxicity requiring permanent cessation (Why this does not fit)
A modest monitored hemodynamic rise does not automatically require stopping a kidney-protective treatment.
B. Reduced angiotensin-mediated efferent tone can lower intraglomerular pressure (Best answer)
This explains a possible initial filtration change and the reduction in proteinuric pressure. Monitor creatinine and potassium; investigate a rise above 30% within four weeks.
C. ACE inhibition constricts the afferent arteriole by blocking prostaglandins (Why this does not fit)
That describes an NSAID-related mechanism, not the ACE inhibitor effect.
D. Monitoring potassium is unnecessary if creatinine rises less than 30% (Why this does not fit)
Hyperkalemia risk still requires assessment independently of the creatinine percentage change.
Takeaway: Understand the pressure effect and monitor it instead of equating every increase with tissue damage.
A. Pure volume depletion with bland sediment (Why this does not fit)
Edema, hypertension, RBC casts, and low complement indicate inflammatory glomerular disease rather than isolated depletion.
B. IgA nephropathy inferred from infection timing alone (Why this does not fit)
IgA-associated hematuria often accompanies a mucosal illness. The delayed low-C3 nephritic syndrome after a documented skin infection is more consistent with poststreptococcal GN.
C. Poststreptococcal glomerulonephritis (Best answer)
The latent interval, nephritic findings, and low C3 fit PSGN. Assess severity, control edema and blood pressure, and eradicate residual streptococcal infection as indicated.
D. Drug-associated AIN proven by RBC casts (Why this does not fit)
RBC casts point toward a glomerular process; there is no drug-related white-cell inflammatory pattern here.
Takeaway: A delayed low-complement nephritic illness after a streptococcal infection identifies a glomerular route to AKI.
